Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Halliburton Company — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $69 (market cap $30.93B), while Halliburton Company trades at $32.99 (market cap $27.35B). The key difference: GE HealthCare Technologies Inc. Common Stock and Halliburton Company are close in size by market cap, and Halliburton Company pays the higher dividend (2.07%). Which is the better fit depends on your goals.
| GEHC | HAL | |
|---|---|---|
Market Cap | $30.93B | $27.35B |
Volume | 5,033,451 | 8,939,895 |
Sector | Health | Energy |
52-Week High | $88.16 | $42.98 |
52-Week Low | $59.48 | $21.82 |
Enterprise Value | $39.39B | $33.50B |
Dividend Yield | 0.23% | 2.07% |
Typical Hold Time | — | 89 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Halliburton (HAL) trades at $32.79, up 0.58% with a bearish technical outlook despite strong analyst support. The company shows solid fundamentals with a P/E of 17.17 and net income margin of 7.16%, though 2025 revenue declined to $22.18B. Recent strategic moves include Venezuela energy agreements and a Cyprus deepwater contract, positioning for international growth. Earnings have consistently beaten expectations, with Q3 2026 results pending.
The stock offers 31% upside to the $43.11 consensus target, supported by 73% buy ratings, but faces headwinds from oil price volatility and execution risks in new markets. Cash flow trends show improvement from 2022's negative $698M to 2026's projected positive $10M, indicating stronger financial health. Valuation remains reasonable relative to sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
